Mylan's generic version of Pfizer birth control injection wins US FDA approval

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

The U.S. Food and Drug Administration approved Mylan NV's generic version of Pfizer Inc.'s birth control injection Depo-Provera.

Mylan is offering the hormonal contraceptive medroxyprogesterone acetate in single-dose vials.

Sales of the drug in the U.S. were about $181 million for the year ending July 31, the company said in an Oct. 18 news release, citing IQVIA data.

Mylan develops and markets generic, brand-name and over-the-counter products worldwide.